VAX-D (Vertebral Axial Decompression) is a non-invasive treatment for the management of patients with chronic back pain and leg pain from lumbar disc or facet joint pathology.
There is no universally accepted algorithm for the care of patients suffering from discogenic back pain. Considerable controversy exists with regards to the efficacy and appropriateness of the various available treatment modalities aimed at relieving pain via neural decompression. Many patients are not satisfied with the effectiveness of the treatment choices offered like drugs, manipulation, physical therapy, exercise, epidural injections, acupuncture, IDET, percutaneous/laser/arthroscopic and open discectomy, and spinal fusion.
In the many patients, acute symptoms resolve in one to two months. Those who fail at the primary care level are routinely referred to orthopedists or neurosurgeons, especially if there is an abnormal CT scan or MRI. The majority are not ideal surgical candidates, and a rush to surgery in the poorly selected patient can led to “failed back syndrome”.
The general goal of surgical treatment is to achieve decompression. It is acknowledged that the many forms of traction, gravity inversion, etc., have not demonstrated the ability to lower disc pressure. Clinical study has documented VAX-D’s ability to lower the intradiscal pressure (Ramos G., Martin W.) and decompress the lumbar discs with no surgical intervention, and no disruption of normal biomechanics.
Physicians can now effectively manage acute and chronic low back problems conservatively. Practitioners can readily acquire competence in the VAX-D protocol and establish their practice as the treatment center of choice for the growing number of low back pain patients.
Low back pain has become one of the most significant medical and socioeconomic problems in the world. Despite the overwhelming statistics on the problem, the number of chronic cases continues to grow. Standardizing the evaluation and care of LBP patients is critical. There is a need for early, effective, target therapy for the treatment of disc pathology.
VAX-D therapy addresses the biomechanical aspects of discogenic disease and should be considered for patients with chronic low back pain with or without radiculopathy if their symptoms have not resolved in the first four weeks.
The VAX-D system is being utilized by leading physicians and surgeons in the fields of Orthopedics, Neurosurgery, Pain Management and Occupational Medicine and Family Practice. VAX-D is being prescribed in the United States, Canada, Mexico, United Kingdom, Colombia, Australia, Spain and Italy. In the many back pain centers across the US, VAX-D has been adopted as the primary treatment for the management of chronic disc disease.
VAX-D therapy is a safe, cost effective, non-surgical treatment that offers new hope for the millions of people who suffer from low back pain everyday. VAX-D celebrates a proud history and commitment to the patients for whom we care, and for those whose lives we can have forever changed.
For further information visit: www.drpeterbrockman.com
No comments:
Post a Comment